Fosun Celebrates Nine Years of CIIE: A Commitment to Global Innovation
On November 5, 2026, the prestigious China International Import Expo (CIIE) kicked off at the National Exhibition and Convention Center in Shanghai, marking its ninth year of promoting international trade and innovation. This year's event is particularly notable, attracting participants from 162 countries and regions, with over 4,100 corporate exhibitors showcasing a record number of new product debuts.
Fosun International, having participated in all nine editions of CIIE, played a significant role in this year's expo by presenting advancements in the healthcare sector, specifically at its Fosun Pharma booth, marked as 2.1C4-01. The presentation featured groundbreaking innovations in drugs and medical devices, focusing on key therapeutic areas such as oncology, immunology, inflammation, and neurodegenerative diseases. Guo Guangchang, Fosun's Chairman, emphasized the importance of the CIIE as a dynamic platform that facilitates innovation and serves as an annual test of global industrial capabilities.
Guo noted, "Over the past nine years, Fosun has transformed world-class technologies exhibited at CIIE into commercial products while empowering international partners to evolve from mere exhibitors to investors. The expo isn't merely about showcasing; it's about fostering a continuous exchange of innovations that can accelerate global market entry."
One of the standout features at the Fosun booth was the da Vinci surgical system, celebrating its 20th anniversary in China with the introduction of the next-generation da Vinci 5. This advanced robotic-assisted surgical system is designed for thoracic and abdominal procedures, marking a significant evolution in minimally invasive surgery capabilities. Furthermore, the event saw the debut of the Breas Apto respiratory mask from Breas Medical, underlining Fosun's commitment to presenting cutting-edge medical technologies.
The journey from exhibition to clinical application is a testament to Fosun's efforts. In collaboration with Intuitive Surgical, Fosun Pharma established a joint venture in 2017 to introduce the da Vinci Xi surgical system at the inaugural CIIE in 2018, which subsequently achieved commercial success in China. Such developments embody Fosun’s mission to facilitate the transition of innovative technologies from concepts displayed at the CIIE to real-world applications that enhance patient care.
This year, Fosun Pharma also showcased additional medical breakthroughs including Akynzeo, the world's first combination antiemetic, and Yi Kai Da, China's pioneering CAR-T cell therapy. Both products highlight Fosun's efforts to not only debut innovations at CIIE but also to ensure their availability to patients through various healthcare channels across China. By optimizing reimbursement practices and enhancing treatment accessibility, Fosun aspires to make medical innovations financially feasible and widely available.
Moreover, Fosun's impact extends beyond domestic innovation. With a robust presence on the global stage, the company aims to accelerate the launch of its innovative drugs in international markets. The efforts include signing strategic partnerships and participating in high-level forums throughout the CIIE to broaden their network and enhance their collaborative capabilities.
Fosun has established a comprehensive supply chain that aligns with international quality standards, easing the process of ensuring a steady supply of medicines globally. As of mid-2026, Fosun Pharma reported the distribution of over 460 million vials of artesunate globally, thereby contributing positively to combat severe malaria.
In conclusion, Fosun's narrative at the CIIE encapsulates a vision that transcends mere participation; it signifies a long-term goal of integrating innovation with accessibility. The message conveyed by Guo Guangchang underscores the commitment of Fosun to leverage the opportunity CIIE presents, not only for product showcasing but also for enhancing the health landscape both in China and internationally. Through ongoing innovation and global partnerships, Fosun continues to drive forward the future of healthcare, ensuring that breakthroughs in medical science reach those in need, transforming patient care worldwide.
Fosun International, having participated in all nine editions of CIIE, played a significant role in this year's expo by presenting advancements in the healthcare sector, specifically at its Fosun Pharma booth, marked as 2.1C4-01. The presentation featured groundbreaking innovations in drugs and medical devices, focusing on key therapeutic areas such as oncology, immunology, inflammation, and neurodegenerative diseases. Guo Guangchang, Fosun's Chairman, emphasized the importance of the CIIE as a dynamic platform that facilitates innovation and serves as an annual test of global industrial capabilities.
Guo noted, "Over the past nine years, Fosun has transformed world-class technologies exhibited at CIIE into commercial products while empowering international partners to evolve from mere exhibitors to investors. The expo isn't merely about showcasing; it's about fostering a continuous exchange of innovations that can accelerate global market entry."
One of the standout features at the Fosun booth was the da Vinci surgical system, celebrating its 20th anniversary in China with the introduction of the next-generation da Vinci 5. This advanced robotic-assisted surgical system is designed for thoracic and abdominal procedures, marking a significant evolution in minimally invasive surgery capabilities. Furthermore, the event saw the debut of the Breas Apto respiratory mask from Breas Medical, underlining Fosun's commitment to presenting cutting-edge medical technologies.
The journey from exhibition to clinical application is a testament to Fosun's efforts. In collaboration with Intuitive Surgical, Fosun Pharma established a joint venture in 2017 to introduce the da Vinci Xi surgical system at the inaugural CIIE in 2018, which subsequently achieved commercial success in China. Such developments embody Fosun’s mission to facilitate the transition of innovative technologies from concepts displayed at the CIIE to real-world applications that enhance patient care.
This year, Fosun Pharma also showcased additional medical breakthroughs including Akynzeo, the world's first combination antiemetic, and Yi Kai Da, China's pioneering CAR-T cell therapy. Both products highlight Fosun's efforts to not only debut innovations at CIIE but also to ensure their availability to patients through various healthcare channels across China. By optimizing reimbursement practices and enhancing treatment accessibility, Fosun aspires to make medical innovations financially feasible and widely available.
Moreover, Fosun's impact extends beyond domestic innovation. With a robust presence on the global stage, the company aims to accelerate the launch of its innovative drugs in international markets. The efforts include signing strategic partnerships and participating in high-level forums throughout the CIIE to broaden their network and enhance their collaborative capabilities.
Fosun has established a comprehensive supply chain that aligns with international quality standards, easing the process of ensuring a steady supply of medicines globally. As of mid-2026, Fosun Pharma reported the distribution of over 460 million vials of artesunate globally, thereby contributing positively to combat severe malaria.
In conclusion, Fosun's narrative at the CIIE encapsulates a vision that transcends mere participation; it signifies a long-term goal of integrating innovation with accessibility. The message conveyed by Guo Guangchang underscores the commitment of Fosun to leverage the opportunity CIIE presents, not only for product showcasing but also for enhancing the health landscape both in China and internationally. Through ongoing innovation and global partnerships, Fosun continues to drive forward the future of healthcare, ensuring that breakthroughs in medical science reach those in need, transforming patient care worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.